Download MendeleyAnti-V1/V3-glycan broadly HIV-1 neutralizing antibodies in a post-treatment controller.
Molinos-Albert, L.M., Baquero, E., Bouvin-Pley, M., Lorin, V., Charre, C., Planchais, C., Dimitrov, J.D., Monceaux, V., Vos, M., Hocqueloux, L., Berger, J.L., Seaman, M.S., Braibant, M., Avettand-Fenoel, V., Saez-Cirion, A., Mouquet, H.(2023) Cell Host Microbe 31: 1275
- PubMed: 37433296
- DOI: https://doi.org/10.1016/j.chom.2023.06.006
- Primary Citation of Related Structures:
8C8T - PubMed Abstract:
HIV-1 broadly neutralizing antibodies (bNAbs) can decrease viremia but are usually unable to counteract autologous viruses escaping the antibody pressure. Nonetheless, bNAbs may contribute to natural HIV-1 control in individuals off antiretroviral therapy (ART). Here, we describe a bNAb B cell lineage elicited in a post-treatment controller (PTC) that exhibits broad seroneutralization and show that a representative antibody from this lineage, EPTC112, targets a quaternary epitope in the glycan-V3 loop supersite of the HIV-1 envelope glycoprotein. The cryo-EM structure of EPTC112 complexed with soluble BG505 SOSIP.664 envelope trimers revealed interactions with N301- and N156-branched N-glycans and the 324 GDIR 327 V3 loop motif. Although the sole contemporaneous virus circulating in this PTC was resistant to EPTC112, it was potently neutralized by autologous plasma IgG antibodies. Our findings illuminate how cross-neutralizing antibodies can alter the HIV-1 infection course in PTCs and may control viremia off-ART, supporting their role in functional HIV-1 cure strategies.
Organizational Affiliation:
Humoral Immunology Unit, Institut Pasteur, Université Paris Cité, INSERM U1222, Paris 75015, France.
